All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health, GSK, and Novartis, and supported through educational grants from Blueprint Medicines and Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
Overall survival with momelotinib vs BAT in ruxolitinib-experienced MF
Results from an unanchored, matching-adjusted indirect comparison (MAIC) analysis, evaluating overall survival (OS) with momelotinib vs best available therapy (BAT) in patients with ruxolitinib-experienced myelofibrosis (MF), were published in Annals of Hematology by Palandri et al. The analysis compared OS data between momelotinib-treated patients from three phase III trials (SIMPLIFY-1 [NCT01969838], SIMPLIFY-2 [NCT02101268], and MOMENTUM [NCT04173494]; n = 383) and patients who received BAT from the RUX‑MF retrospective real-world study (NCT06516406; n = 267).
Key data: The MAIC analysis demonstrated a significant OS benefit with momelotinib vs BAT in the overall population; hazard ratios (HRs) were 0.525 in model 1 (momelotinib effective sample size [ESS] = 89; 95% confidence interval [CI], 0.375–0.737; p < 0.001) and 0.486 in model 2 (momelotinib ESS = 117; 95% CI, 0.353–0.668; p < 0.001). Findings were consistent across sensitivity analyses, with matched HRs ranging from 0.474 to 0.561. In the anemic subgroup (momelotinib, n = 255; BAT, n = 174), matched analyses showed longer OS with momelotinib vs BAT, with HRs of 0.565 in model 1 (momelotinib, ESS = 98; 95% CI, 0.413–0.772; p < 0.001) and 0.503 in model 2 (momelotinib, ESS = 146; 95% CI, 0.379–0.668; p < 0.001).
Key learning: Momelotinib demonstrated a favorable OS benefit vs BAT in patients with ruxolitinib-experienced MF, supporting its consideration as a treatment option in this challenging clinical setting, particularly for anemic patients.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
